Gamida Cell Ltd.

212 articles about Gamida Cell Ltd.

• 

  Gamida Cell Taps Former Clal Biotech CSO as New Leader

  11/20/2017

  Dr. Adams to further advance promising pipeline, including breakthrough therapy, NiCord, in phase 3 development as a universal bone marrow transplant solution.

• Gamida Cell to Present New Data from Key Programs at 2017 ASH Annual Meeting

  11/2/2017

  The oral presentations will highlight safety and efficacy data for a completed phase 2 study of the company’s lead clinical asset, NiCord, as a single cord blood graft, and proof-of-concept data for the advancement of natural killer cells (NK cells) as an immunotherapeutic modality for patients with cancer.

• Gamida Cell Announces First Patient Transplanted In Phase I/II Study Of CordIn For Severe Aplastic Anemia And Hypoplastic MDS

  8/21/2017

• Gamida Cell Announces $3.5 Million Grant From The Israeli Government

  7/20/2017

• Gamida Cell Names Ronit Simantov, M.D. As Chief Medical Officer

  7/10/2017

• Israel's Gamida Cell Banks $40 Million For Bone Marrow Trial

  6/19/2017

• Gamida Cell Appoints Nobel Prize Laureate Professor Roger Kornberg And Immune Oncology Expert Dr. Michael Perry To Its Board Of Directors

  6/5/2017

• Gamida Cell Announces Publication Of Positive Clinical Outcomes From NiCord-Transplanted Patients In The Journal Of Biology Of Blood And Marrow Transplantation

  4/20/2017

• Gamida Cell Receives Additional EMA Orphan Drug Designation For Nicord In Haematopoietic Stem Cell Transplantation (HSCT)

  3/23/2017

• Gamida Cell Announces First Patient Transplanted In Phase III Registration Study Of Nicord For Blood Cancers

  2/28/2017

• Gamida Cell Presents Positive Data From Phase 1/2 Study Of NiCord as A Curative Treatment For Sickle Cell Disease At American Society of Hematology 2016

  12/6/2016

• Gamida Cell Names Julian Adams, Ph.D. New Chairman Of The Board

  11/21/2016

• Novartis AG-Backed Gamida Cell Nabs Breakthrough Tag for NiCord

  10/11/2016

• Gamida Cell Announces Appointment Of Julian Adams, Ph.D. And Kenneth I. Moch To Its Board Of Directors

  9/15/2016

• Gamida Cell Announces First Patient With Sickle Cell Disease Transplanted In Phase 1/2 Study Of Cordin As The Sole Graft Source

  7/27/2016

• ASCO2016: Gamida Cell Presents Data From Phase 1/2 Study Of Nicord For High Risk Hematological Malignancies At ASCO 2016

  6/6/2016

• Gamida Cell Announces $4.4 Million Grant From The Israeli Government

  5/23/2016

• Gamida Cell Presents Additional Positive Data Of NiCord In Blood Cancer Patients At EBMT 2016

  4/5/2016

• Gamida Cell Reports Positive Top Line Results Of International, Multi-Center, Phase I/II Study Of Nicord For Blood Cancers, Demonstrating Rapid And Durable Hematopoietic Recovery

  12/7/2015

• Novartis AG Takes Another 2.5% Stake in Gamida Cell

  10/12/2015